Get the Stockscreener App
0.7755
4.73%
0.035
After Hours:
.80
0.0245
+3.16%
Dare Bioscience Inc stock is traded at $0.7755, with a volume of 117.38K.
It is up +4.73% in the last 24 hours and down -5.51% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$0.7405
Open:
$0.77
24h Volume:
117.38K
Relative Volume:
0.28
Market Cap:
$15.25M
Revenue:
$1.16M
Net Income/Loss:
$-12.02M
P/E Ratio:
-0.747
EPS:
-1.0381
Net Cash Flow:
$-10.16M
1W Performance:
-1.12%
1M Performance:
-5.51%
6M Performance:
-44.61%
1Y Performance:
-62.72%
1-Day Range:
$0.7458
$0.7895
1-Week Range:
$0.7117
$0.88
52-Week Range:
$0.69
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
0.7755 | 15.25M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc Stock (DARE) Latest News
Daré Bioscience launches Flora Sync LF5 for direct revenue - scanx.trade
Warrants covering about 45% of existing shares await a vote at Daré Bioscience (NASDAQ: DARE). - Stock Titan
Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daré Bioscience publishes phase 1 sildenafil cream study data - Investing.com
Dare Bioscience (DARE) Reports Phase 1 Trial Results for Topical Sildenafil Cream - GuruFocus
Daré Bioscience publishes phase 1 sildenafil cream study data By Investing.com - Investing.com India
Sildenafil cream showed 187-fold lower peak blood levels than an oral dose - Stock Titan
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com Australia
Dare Bioscience amends bylaws to lower quorum for shareholder meetings By Investing.com - Investing.com Australia
Daré Bioscience Updates Bylaws to Ease Shareholder Quorum - TipRanks
Dare Bioscience amends bylaws to lower quorum for shareholder meetings - Investing.com
Daré Bioscience at H.C. Wainwright conference: turning to sales By Investing.com - Investing.com Canada
Daré Bioscience at H.C. Wainwright conference: turning to sales - Investing.com
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand - The Manila Times
Daré Bioscience Presentation for H.C. Wainwright 28th - GlobeNewswire
Daré Bioscience Updates Investors with New Presentation - TipRanks
DARE|Dare Bioscience Inc|Price:0.713|Chg%:-0.008 - TradingKey
Dare Bioscience (NASDAQ: DARE) Eyes Up to $12.4M from Warrants to Boost 503B and Consumer Health Initiatives - kalkinemedia.com
Dare Bioscience, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Dare Bioscience Inc (DARE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Dare Bioscience Inc (DARE) Key Financial Ratios – Valuation, Profitability & More - Value Research
Dare Bioscience (DARE) Secures $908K NIH Grant Amidst Challengin - GuruFocus
Daré Bioscience receives $908,000 NIH award for preterm birth program - Investing.com India
Daré Bioscience receives $908,000 NIH award for preterm birth program By Investing.com - Investing.com Nigeria
Daré Bioscience Announces New NIH Funding Award for - GlobeNewswire
Lind Global’s capped stake in Dare Bioscience (NASDAQ: DARE) tops key ownership threshold - Stock Titan
Dare Bioscience Inc (DARE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - Barchart.com
IPO Databook: Daré Bioscience (DARE US)Aug 2026 - Smartkarma
Daré Bioscience publishes sildenafil cream study results - Investing.com
Daré Bioscience publishes sildenafil cream study results By Investing.com - Investing.com India
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - Barchart.com
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment - Yahoo Finance
L1 Capital caps Dare Bioscience (DARE) stake at 9.99% - Stock Titan
Drugmakers still struggling to keep up with spiking estrogen patch demand - AOL.com
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - AOL.com
Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash - Stock Titan
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - sahmcapital.com
Forbes puts a women's health biotech CEO on its 2026 innovation list - Stock Titan
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: C - GuruFocus
Dare Bioscience Prices $6.0 Million Registered Direct Offering - Minichart
Form 8K Dare Bioscience Inc For: 17 August By Investing.com - Investing.com Nigeria
Daré Bioscience Raises ~$6 Million in Equity Offering at $1.37 With Attached Warrants - TradingView
H.C. Wainwright reiterates Dare Bioscience stock rating at buy By Investing.com - Investing.com Canada
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ... - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Q2 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):